Quality-by-Design-Based Mucoadhesive Intranasal Nanoemulsion of Lumateperone: A Review

  • Unique Paper ID: 211168
  • Volume: 13
  • Issue: 6
  • PageNo: 3582-3590
  • Abstract:
  • Lumateperone is an oral antipsychotic approved for schizophrenia and bipolar depression. Intranasal nanoemulsions have been studied for several other antipsychotics as a way to reach the brain through the nose. This review asks whether a mucoadhesive intranasal nanoemulsion of lumateperone, developed by Quality by Design (QbD), is a reasonable next step. We read the abstracts of 45 papers on lumateperone pharmacology and clinical trials, nose-to-brain delivery, nanoemulsion science, mucoadhesive antipsychotic formulations and design of experiments. In animals, intranasal nanoemulsions of risperidone, paliperidone and quetiapine gave higher brain uptake or better behavioural effects than their comparators, and chitosan was the usual mucoadhesive agent. We found no lumateperone nanoformulation of any kind, no abstract that reports its solubility or lipophilicity, and no nasal study of the drug. We propose a QbD pathway with a target product profile, critical attributes, a Box-Behnken design and a set of in-vitro tests. The design is conceptual and no experimental data are reported.

Copyright & License

Copyright © 2026 Authors retain the copyright of this article. This article is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

BibTeX

@article{211168,
        author = {Khushi Singh and Mohd Jalaluddin and Sanjay Chaurasia},
        title = {Quality-by-Design-Based Mucoadhesive Intranasal Nanoemulsion of Lumateperone: A Review},
        journal = {International Journal of Innovative Research in Technology},
        year = {2026},
        volume = {13},
        number = {6},
        pages = {3582-3590},
        issn = {2349-6002},
        url = {https://ijirt.org/article?manuscript=211168},
        abstract = {Lumateperone is an oral antipsychotic approved for schizophrenia and bipolar depression. Intranasal nanoemulsions have been studied for several other antipsychotics as a way to reach the brain through the nose. This review asks whether a mucoadhesive intranasal nanoemulsion of lumateperone, developed by Quality by Design (QbD), is a reasonable next step. We read the abstracts of 45 papers on lumateperone pharmacology and clinical trials, nose-to-brain delivery, nanoemulsion science, mucoadhesive antipsychotic formulations and design of experiments. In animals, intranasal nanoemulsions of risperidone, paliperidone and quetiapine gave higher brain uptake or better behavioural effects than their comparators, and chitosan was the usual mucoadhesive agent. We found no lumateperone nanoformulation of any kind, no abstract that reports its solubility or lipophilicity, and no nasal study of the drug. We propose a QbD pathway with a target product profile, critical attributes, a Box-Behnken design and a set of in-vitro tests. The design is conceptual and no experimental data are reported.},
        keywords = {Lumateperone; intranasal nanoemulsion; mucoadhesion; chitosan; nose-to-brain delivery; Quality by Design; Box-Behnken design; schizophrenia},
        month = {November},
        }

Cite This Article

Singh, K., & Jalaluddin, M., & Chaurasia, S. (2026). Quality-by-Design-Based Mucoadhesive Intranasal Nanoemulsion of Lumateperone: A Review. International Journal of Innovative Research in Technology (IJIRT), 13(6), 3582–3590.

Related Articles